Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Financial Performance and Competitive Landscape

Core Insights - Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics aimed at silencing specific genes related to various diseases, positioning itself competitively alongside peers like BioMarin, Ionis, Sarepta, and Agios [1] Financial Performance - Alnylam has a Return on Invested Capital (ROIC) of 13.74% and a Weighted Average Cost of Capital (WACC) of 5.69%, resulting in a ROIC to WACC ratio of 2.42, indicating effective capital utilization [2][5] - In contrast, Ionis Pharmaceuticals has a ROIC of -9.98% and a WACC of 5.25%, leading to a negative ROIC to WACC ratio of -1.90, while Sarepta and Agios also report negative ratios of -1.04 and -4.91 respectively [3][5] Capital Efficiency - Alnylam's ROIC to WACC ratio of 2.42 positions it as a leader in capital efficiency among its peers, suggesting it is effectively utilizing its capital to generate returns [4][5]